Ann: March Quarterly Activity and Cashflow Report, page-13

First 13 Last

Share
Profile

Follow
StockObserver

1,308 Posts.

583

30/04/20

19:43

Post #: 44364483
Share

Originally posted by divvv10: ↑

So I've had a look through the quarterly of other cannabis stocks, mainly to have a look at their sales/receipts, manufacturing costs, total loss for the quarter and staff/administration costs.

It was also interesting to see the generous government grants and tax incentives some companies received which really helped the bank balance.

For me, it was more a matter of comparing and seeing that most other companies seem to be struggling with cost of sales and expenses. Yes, our burn rate is high (research expenses sure did contribute to that figure), but you start to see that our numbers don't stack up that badly compared to the rest of the competition.

We are up there with sales and one of the lowest when it comes to staff/administration costs. We did not receive any government grants and/or tax incentives this quarter - despite some companies receiving generous incentives.

Even our loss is relatively the same as the rest of the sector.

In order from highest sales/receipts:

EXL - $3.97mil receipts / manufacturing costs $4.643mil (total $9.049mil loss)
- $7.024mil staff/administration costs
- $0 government grant and/or receipts

CPH - $1.44mil receipts / $667k manufacturing costs (total $1.164mil loss)
- $1.9mil staff/administration costs
- $0 government grant and/or tax incentive

BDA - $1.257mil receipts / $923k manufacturing costs (total $884k loss)
- $891k staff/administration costs
- 884k government grant and/or tax inventive

THC - $1.22mil receipts / manufacturing costs $1.055mil (total $1.7mil loss)
- $1.815mil staff/administration costs
- $193k government grant and/or tax incentive

CAN - 12k receipts / manufacturing costs $1.67mil (total 3.32mil loss for the quarter)
- $2.514mil staff/administration costs
- $502k government grant and/or tax incentive.

LGP - $630k receipts / cost of sales $521k (total $2.2mil loss)
- $1.9mil staff/administration costs
- $0 government grant and/or tax incentive

MXC - $832k receipts / $798k manufacturing costs (total $1.8mil loss)
- $823k staff/administration costs
- $0 government grant and/or tax incentive

AC8 - $0 receipts / $392k manufacturing costs (total $522k loss)
- $1.21mil staff/administration costs
- $1.2mil government grant and/or tax incentive

ZLD - $234k receipts / $0 manufacturing costs (total $1.5mil loss)
- $357,000 staff/administration costs
- $0 government grant and/or tax incentive

BOT - $0 receipts / $0 manufacturing costs (total $3.1mil positive)
- $1.392mil staff/administration costs
- $7.56mil government grant and/or tax incentives

CP1 – $0 receipts / $0 manufacturing costs (total $5k positive)
- $105k staff/administration costs
- 589k government grant and/or tax inventive

The biotech game is a tough sector (especially for start ups), millions of dollars pumped into research and development in the hope of being able to commercialise on it all.

Expand

Pretty fair analysis but slightly selective. For instance, any reason for leaving out AGH and MDC from these comparisons?

MXC Price at posting: 2.8¢ Sentiment: Sell Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

IRE

Iress runs 'hot' for Wealth Within's stock tips

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Failure to report prompts ASX to impose multiple company suspensions

There are more pages in this discussion • 7 more messages in this thread...

First 13 Last

Add RGT (ASX) to my watchlist

(20min delay)
Last 53.0¢		Change 0.180(51.4%)		Mkt cap ! $25.65M

Open	High	Low	Value	Volume
38.0¢	56.0¢	38.0¢	$71.38K	137.5K

Buyers (Bids)

No.	Vol.	Price($)
1	334	51.0¢

Sellers (Offers)

Price($)	Vol.	No.
55.0¢	60	1

View Market Depth

No.	Vol.	Price($)
1	334	0.510
1	680	0.470
1	2000	0.460
1	5000	0.450
2	9000	0.445

Price($)	Vol.	No.
0.550	60	1
0.590	2000	1
0.620	1414	1
0.700	1368	1
0.740	350	1

Last trade - 16.10pm 01/10/2024 (20 minute delay)

RGT (ASX) Chart

Ann: March Quarterly Activity and Cashflow Report, page-13

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Iress runs 'hot' for Wealth Within's stock tips

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Failure to report prompts ASX to impose multiple company suspensions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: March Quarterly Activity and Cashflow Report, page-13

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Iress runs 'hot' for Wealth Within's stock tips

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Failure to report prompts ASX to impose multiple company suspensions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News